HSBC analyst Rajesh Kumar yesterday upgraded Roche (RHHBY) to Buy from Hold with a $50 price target The firm sees upside to the company’s revenue estimates and obesity trial readouts could drive share upside. Roche shares offer an attractive risk/reward profile, the analyst told investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Trump Trade: White House announces drug pricing deal with Pfizer
- Trump outlines plan for next round of Medicare drug price talks, Bloomberg says
- White House announces deal with Pfizer for ‘most-favored-nation pricing’
- Trump says other drugmakers to join Pfizer with ‘most favored nation’ prices
- Disc Medicine submits NDA to FDA for bitopertin in patients with EPP